Headquartered in New York, NY Fiscal year ends December NYSE: PFE pfizer.com
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide.
**Business structure**
Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions:
- Pfizer U.S. Commercial Division
- Pfizer International Commercial Division
- Global Hospital and Biosimilars Division
**Product portfolios**
- **Primary Care:** Eliquis, the Prevnar family, Nurtec ODT/Vydura, Comirnaty, Abrysvo, Paxlovid and FSME-IMMUN/TicoVac.
- **Oncology:** Ibrance, Padcev, Xtandi, Lorbrena, Inlyta, Braftovi/Mektovi, Adcetris, Orgovyx, Tukysa, Bosulif, Elrexfio, Talzenna and Tivdak.
- **Specialty Care:** the Vyndaqel family, Xeljanz, Zavicefta, Enbrel, Octagam, BeneFIX, Cresemba, Genotropin and Cibinqo.
- **Hospital and Biosimilars (formed in 2026):** off-patent sterile injectables and biosimilars such as Retacrit, Ruxience, Zirabev, Inflectra and Sulperazon.
**Other operations and revenue sources**
- Pfizer CentreOne provides contract manufacturing and active pharmaceutical ingredient sales.
- Revenue comes from product sales, alliance revenues (e.g., Eliquis, Xtandi, Orgovyx) and royalties.
- The U.S. accounts for roughly two-thirds of sales.
**Strategy**
Pfizer is shifting away from declining COVID-19 products toward launched and acquired medicines, including those from the Seagen acquisition. It is investing in oncology, obesity, immunology and next-generation vaccine programs. It is also executing an enterprise-wide cost realignment and de-levering its balance sheet. Updated
Pfizer is outrunning its COVID hangover: Paxlovid sales fell 63%, yet full-year revenue guidance rose to $62 billion to $64 billion. That is the seventh straight quarter of topping EPS expectations.
Pfizer cleared $30 for the first time in a year, closing at $30.52 and topping its October 22 peak by 0.33%. The $173.9 billion drugmaker was trading near $23 twelve months ago.
Pfizer hit a fresh 52-week high at $29.21, topping its September 2 peak. The drugmaker is now trading at levels no buyer from the past year is underwater on.
Five stocks cleared 52-week highs this week: Dell topped its prior peak by 6% at $524.14, with Snowflake close behind at 5.7%. Box, Pfizer and Chevron rounded out the list with narrower breakouts.
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.52, up 5% in afternoon trading, as the…
Six high-yield stocks, one portfolio, and two very different tax bills waiting at the end of each year. Where you hold these positions matters far more than most investors realize before they…
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything. Whether the…
Four stocks are paying out billions in dividends that their cash flows can barely support, and the gap between what investors expect and what the business can actually deliver keeps widening. Before…
Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has…
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or pile in, the real…
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook. However, Merck’s steady, Keytruda-anchored growth tells a very different…
Some of the fattest dividend yields on the market right now come from stocks that have already cut their payouts once, and three more may be quietly building toward the same moment.…
Pfizer (NYSE:PFE | PFE Price Prediction) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date. This report tests whether non-COVID growth and obesity progress…
Rich Duprey Parking six popular dividend stocks in a taxable account quietly hands the IRS a cut of every payout, and one holding in your portfolio is almost certainly the biggest culprit.
Three companies in pharmaceuticals, energy, and tobacco operate in entirely different worlds, and that separation is exactly the point for retirees who need their income to survive whatever the market throws at…
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial. Moderna (NASDAQ:MRNA | MRNA…
A flashy dividend yield can mask serious cracks in a company's finances, and four well-known names are showing the same warning signs that preceded Whirlpool's sudden payout suspension earlier this year.
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn’t stopped. Those numbers landed short of the…
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide. **Business structure** Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions: - Pfizer U.S.
24/7 Wall St.'s 12-month price target for PFE is $34.02, rated Buy. The Wall Street consensus target is $29.26. PFE price prediction →
